Overview

Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)

Status:
Not yet recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

This is an open-label, non-randomized, fixed-sequence study. Subjects will undergo a rosuvastatin phase and eltrombopag and rosuvastatin phase to identify biomarkers for Breast Cancer Resistance Protein (BCRP).

Phase:

Phase 1

Details

Lead Sponsor:

University of California, San Francisco

Collaborator:

Food and Drug Administration (FDA)

Treatments:

Rosuvastatin Calcium